接受抗凝治疗的静脉血栓栓塞症患者的出血风险及出血风险评估模型的效能:来自前瞻性观察性BACH-VTE研究的结果
BACH-VTE前瞻性观察性队列纳入308例急性VTE起始抗凝患者,中位随访12.6个月。2年任何出血累积发生率33.4%,临床相关出血16.2%,大出血0.9%。VTE-PREDICT模型区分度可接受(C统计量0.71)但校准差,其余模型区分度差。
要点
- VTE抗凝患者2年临床相关出血累积发生率为16.2%,任何出血为33.4%。
- VTE-PREDICT对临床相关出血的C统计量为0.71,区分度可接受但校准低估出血风险。
- HAS-BLED、RIETE和VTE-BLEED的C统计量分别为0.59、0.52和0.56,区分度差。
核心结论
- 在接受抗凝治疗的VTE患者中观察到较高的临床相关出血发生率;仅VTE-PREDICT模型显示出可接受的区分度,但校准差。
研究设计与样本
- 前瞻性观察性队列研究(BACH-VTE),纳入急性VTE起始抗凝治疗患者,随访至多2年,排除活动性癌症、妊娠和产后期患者,共308例。
主要发现
- 中位随访12.6个月,观察到大出血2例、临床相关非大出血41例、轻微出血66例。
- 2年累积发生率(95%CI):大出血0.9%(0%-2.1%),临床相关非大出血16.2%(10.7%-21.3%),轻微出血20.6%(15.1%-25.8%),任何出血33.4%(26.7-39.5)。
- 临床相关出血的C统计量(95%CI):VTE-PREDICT为0.71(0.61-0.80),HAS-BLED为0.59(0.49-0.68),RIETE为0.52(0.41-0.62),VTE-BLEED为0.56(0.45-0.68)。
- 校准分析显示出血风险被低估。
- 女性、较低血红蛋白和出血史在单变量模型中与临床相关出血相关,但在多变量模型中不相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with venous thromboembolism (VTE) are at risk of bleeding during anticoagulation. OBJECTIVES: This study aimed to assess bleeding risk and the performance of risk assessment models (RAMs) VTE-PREDICT, HAS-BLED, RIETE, and VTE-BLEED in patients with acute VTE initiating anticoagulation. METHODS: We used data from a prospective observational cohort study (BACH-VTE) including patients with acute VTE who initiated anticoagulation with a follow-up period of up to 2 years. Exclusion criteria were active cancer, pregnancy, and postpartum period. Major bleeding, clinically relevant nonmajor bleeding (CRNMB), and minor bleeding were recorded and their frequencies calculated. RAM performance was evaluated by discrimination and calibration. Predictors associated with clinically relevant bleeding (CRB; composite of major and CRNMB) were assessed. RESULTS: In total, 308 patients (median age, 55 years; 42% women, 47% pulmonary embolism, 62% unprovoked VTE) were included. During a median follow-up time of 12.6 months, we observed 2 major bleedings, 41 CRNMBs, and 66 minor bleedings, corresponding to 2-year cumulative incidences (95% CI) of 0.9% (0%-2.1%), 16.2% (10.7%-21.3%), and 20.6% (15.1%-25.8%), respectively, and of 33.4% (26.7-39.5) for any bleeding. RAM discrimination was poor to moderate with C-statistics (95% CI) for CRB of 0.71 (0.61-0.80) for VTE-PREDICT, 0.59 (0.49-0.68) for HAS-BLED, 0.52 (0.41-0.62) for RIETE, and 0.56 (0.45-0.68) for VTE-BLEED. Calibration analysis revealed underestimation of bleeding risk. Female sex, lower hemoglobin, and bleeding history were associated with CRB in a univariable but not in a multivariable model. CONCLUSION: In patients treated with anticoagulants for VTE, we found high rates of CRB. Only the VTE-PREDICT model showed acceptable discrimination, but poor calibration.
引用
- Hoberstorfer T, Nopp S, Steiner D, et al. Bleeding risk and performance of bleeding risk assessment models in patients with venous thromboembolism on anticoagulation: results from the prospective observational bleeding and assess long-term outcomes on health in patients with venous thromboembolism (BACH-VTE) study. J Thromb Haemost. 2025. PMID: 40379106. doi:10.1016/j.jtha.2025.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。